Search

Arcutis Biotherapeutics Inc

Geschlossen

BrancheGesundheitswesen

23.51 -3.13

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

23.82

Max

24.73

Schlüsselkennzahlen

By Trading Economics

Einkommen

26M

15M

Verkäufe

24M

130M

KGV

Branchendurchschnitt

108.636

56.597

EPS

0.11

Gewinnspanne

11.558

Angestellte

354

EBITDA

23M

17M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+53.11% upside

Dividenden

By Acuity

Nächstes Ergebnis

27. Okt. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-241M

3B

Vorheriger Eröffnungskurs

26.64

Vorheriger Schlusskurs

23.51

Nachrichtenstimmung

By Acuity

44%

56%

97 / 339 Ranking in Healthcare

Arcutis Biotherapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

14. Sept. 2026, 20:02 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing, having rebounded from an early session low amid broader market concerns over rising crude oil prices.

11. Sept. 2026, 19:46 UTC

Arcutis Biotherapeutics is gaining today, reaching earlier highs amid broader market reactions to Consumer Price Index data and interest rate speculation.

10. Sept. 2026, 23:06 UTC

Arcutis Biotherapeutics shares are lower in after-market hours, continuing a downward trend observed over the past three sessions. The price remains below the 20-day moving average.

9. Sept. 2026, 19:26 UTC

Arcutis Biotherapeutics is declining amid broader market pressure from rising crude oil prices, which reached $100.49 per barrel during Wednesday's session.

8. Sept. 2026, 23:41 UTC

Arcutis Biotherapeutics shares rose in after-market trading, marking a shift from the recent trend of higher daily closes since Tuesday's close.

4. Sept. 2026, 20:07 UTC

News

Arcutis Biotherapeutics granted 57,000 RSUs to new employees, supporting growth initiatives. Shares are higher since Thursday's close despite a pullback earlier in the session.

1. Sept. 2026, 20:01 UTC

Arcutis Biotherapeutics Inc. shares are lower today, trading significantly below the 20-day moving average amid rising oil prices and inflation concerns.

31. Aug. 2026, 19:36 UTC

Arcutis Biotherapeutics Inc shares are higher today, recovering from earlier losses despite no specific news to explain the price movement.

28. Aug. 2026, 22:56 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, though no specific news was identified. Broader market conditions may influence this movement.

26. Aug. 2026, 20:08 UTC

Arcutis Biotherapeutics Inc shares are higher Wednesday, pulling back from session highs. Broader market fluctuations follow inflation data indicating rising consumer prices.

25. Aug. 2026, 19:36 UTC

News

Arcutis Biotherapeutics shares are gaining as board member Terrie Curran exercised options for 1,072 shares valued at $18,642, according to an SEC filing.

24. Aug. 2026, 19:16 UTC

Arcutis Biotherapeutics Inc. shares are trading lower, continuing a downward trend amid broader market dynamics and ahead of upcoming macroeconomic developments.

21. Aug. 2026, 19:56 UTC

Event

Arcutis Biotherapeutics Inc. is trading lower despite Health Canada's approval of PrZORYVE® cream for pediatric atopic dermatitis. The stock continues a downward trend since Thursday.

20. Aug. 2026, 19:51 UTC

News

Arcutis Biotherapeutics Inc shares are lower despite Health Canada approving ZORYVE cream for pediatric atopic dermatitis, amid broader Biotechnology sector weakness.

19. Aug. 2026, 19:26 UTC

Shares of Arcutis Biotherapeutics Inc. are higher today, maintaining an upward trajectory despite a modest pullback from an early high earlier in the session.

18. Aug. 2026, 19:56 UTC

Arcutis Biotherapeutics Inc shares are higher today, following a notable peak earlier. The overall move remains positive since Monday's close amid rising Treasury yields.

14. Aug. 2026, 20:06 UTC

Shares of Arcutis Biotherapeutics Inc. are advancing today, despite mixed market sentiment following a reported decline in U.S. retail sales for July.

13. Aug. 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading lower with no specific news identified. The stock is below its 20-day moving average after recent gains.

12. Aug. 2026, 19:46 UTC

Arcutis Biotherapeutics Inc is trading higher amid positive market sentiment following a favorable inflation report, contributing to gains in major U.S. indices.

11. Aug. 2026, 23:46 UTC

Arcutis Biotherapeutics shares are higher in after-market trading, reflecting broader market anticipation of modest inflation in the upcoming consumer price index report.

10. Aug. 2026, 19:36 UTC

Arcutis Biotherapeutics Inc is trading higher, rebounding from earlier lows. The stock remains below its 20-day moving average and near its one-month range.

7. Aug. 2026, 23:31 UTC

News

Arcutis Biotherapeutics granted 143,500 RSUs and options to new hires. Shares are trading higher in after-market hours following the announcement.

6. Aug. 2026, 22:16 UTC

Shares of Arcutis Biotherapeutics Inc. are trading higher in after-market hours, amid cautious investor sentiment following recent jobless claims data.

5. Aug. 2026, 23:02 UTC

News
Social Media

Arcutis Biotherapeutics reports Q2 net product revenues of $129.9 million and raises full-year sales guidance to $525 million to $540 million. Shares rise in after-market trading.

4. Aug. 2026, 19:46 UTC

Arcutis Biotherapeutics is advancing during Tuesday's session amid a broader market boost from declining crude oil prices, easing inflation concerns.

3. Aug. 2026, 21:01 UTC

Arcutis Biotherapeutics Inc shares are lower in after-market trading, continuing a decline despite broader market gains and optimism over lower oil prices.

31. Juli 2026, 20:03 UTC

Arcutis Biotherapeutics Inc shares are lower today, continuing a decline since Thursday's close amid broader weak performance and no specific news identified.

30. Juli 2026, 23:51 UTC

Arcutis Biotherapeutics shares are lower in after-market trading, reflecting a broader decline since Thursday's close amid mixed Asian equity performance and geopolitical concerns.

29. Juli 2026, 19:19 UTC

Arcutis Biotherapeutics Inc. shares are lower as market sentiment reflects concerns over the Federal Reserve's upcoming monetary policy announcement amid inflationary pressures.

28. Juli 2026, 18:06 UTC

Arcutis Biotherapeutics Inc. shares are higher today, supported by a broader rally in biotechnology stocks, despite no specific company news identified.

Peer-Vergleich

Kursveränderung

Arcutis Biotherapeutics Inc Prognose

Kursziel

By TipRanks

53.11% Vorteil

12-Monats-Prognose

Durchschnitt 36.571 USD  53.11%

Hoch 40 USD

Tief 34 USD

Basierend auf 7 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Arcutis Biotherapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

7 ratings

7

Buy

0

Halten

0

Sell

Stimmung

By Acuity

97 / 339 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
help-icon Live chat